Mirador Capital Partners’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $17.3M | Buy |
68,762
+2,881
| +4% | +$620K | 2.12% | 10 |
|
|
2026
Q1 | $14.3M | Buy |
65,881
+833
| +1% | +$185K | 2.03% | 10 |
|
|
2025
Q4 | $14.9M | Buy |
65,048
+1,346
| +2% | +$307K | 2.04% | 13 |
|
|
2025
Q3 | $14.7M | Buy |
63,702
+3,311
| +5% | +$674K | 2.09% | 13 |
|
|
2025
Q2 | $11.2M | Buy |
60,391
+5,667
| +10% | +$1.05M | 1.82% | 14 |
|
|
2025
Q1 | $11.5M | Buy |
54,724
+2,534
| +5% | +$493K | 2.01% | 13 |
|
|
2024
Q4 | $9.27M | Sell |
52,190
-417
| -0.8% | -$76.7K | 1.68% | 14 |
|
|
2024
Q3 | $10.4M | Buy |
52,607
+976
| +2% | +$182K | 1.87% | 14 |
|
|
2024
Q2 | $8.86M | Buy |
51,631
+1,651
| +3% | +$273K | 1.67% | 14 |
|
|
2024
Q1 | $9.1M | Buy |
49,980
+1,625
| +3% | +$280K | 1.74% | 13 |
|
|
2023
Q4 | $7.49M | Sell |
48,355
-1,219
| -2% | -$178K | 1.59% | 14 |
|
|
2023
Q3 | $7.39M | Sell |
49,574
-561
| -1% | -$82.4K | 1.68% | 10 |
|
|
2023
Q2 | $6.75M | Buy |
50,135
+885
| +2% | +$130K | 1.6% | 12 |
|
|
2023
Q1 | $7.85M | Sell |
49,250
-1,513
| -3% | -$231K | 1.86% | 13 |
|
|
2022
Q4 | $8.2M | Buy |
50,763
+553
| +1% | +$84.8K | 1.94% | 11 |
|
|
2022
Q3 | $6.74M | Sell |
50,210
-1,083
| -2% | -$155K | 1.63% | 15 |
|
|
2022
Q2 | $7.86M | Buy |
51,293
+1,493
| +3% | +$228K | 1.85% | 13 |
|
|
2022
Q1 | $8.07M | Buy |
49,800
+3,395
| +7% | +$493K | 1.63% | 15 |
|
|
2021
Q4 | $6.28M | Buy |
46,405
+3,625
| +8% | +$428K | 1.32% | 21 |
|
|
2021
Q3 | $4.62M | Buy |
42,780
+721
| +2% | +$82.4K | 1.05% | 28 |
|
|
2021
Q2 | $4.74M | Buy |
42,059
+2,084
| +5% | +$235K | 1.07% | 30 |
|
|
2021
Q1 | $4.33M | Buy |
39,975
+2,676
| +7% | +$286K | 1.11% | 28 |
|
|
2020
Q4 | $4M | Buy |
37,299
+1,222
| +3% | +$117K | 1.1% | 28 |
|
|
2020
Q3 | $3.16M | Sell |
36,077
-1,295
| -3% | -$122K | 0.98% | 34 |
|
|
2020
Q2 | $3.67M | Buy |
37,372
+207
| +0.6% | +$18.2K | 1.37% | 20 |
|
|
2020
Q1 | $3.17M | Buy |
37,165
+3,751
| +11% | +$319K | 1.33% | 22 |
|
|
2019
Q4 | $2.96M | Sell |
33,414
-483
| -1% | -$40.1K | 1.19% | 24 |
|
|
2019
Q3 | $2.57M | Buy |
33,897
+1,687
| +5% | +$116K | 1.15% | 27 |
|
|
2019
Q2 | $2.34M | Buy |
32,210
+15,819
| +97% | +$1.24M | 1.15% | 27 |
|
|
2019
Q1 | $1.32M | Sell |
16,391
-620
| -4% | -$50.7K | 0.72% | 48 |
|
|
2018
Q4 | $1.57M | Sell |
17,011
-2,212
| -12% | -$195K | 0.97% | 40 |
|
|
2018
Q3 | $1.82M | Buy |
19,223
+78
| +0.4% | +$7.4K | 0.89% | 44 |
|
|
2018
Q2 | $1.77M | Sell |
19,145
-239
| -1% | -$23.3K | 0.97% | 36 |
|
|
2018
Q1 | $1.87M | Sell |
19,384
-197
| -1% | -$21.6K | 1.31% | 25 |
|
|
2017
Q4 | $1.89M | Buy |
19,581
+284
| +1% | +$26.8K | 1.04% | 34 |
|
|
2017
Q3 | $1.74M | Buy |
19,297
+124
| +0.6% | +$9.44K | 1.02% | 36 |
|
|
2017
Q2 | $1.36M | Sell |
19,173
-244
| -1% | -$16.4K | 0.83% | 38 |
|
|
2017
Q1 | $1.26M | Buy |
19,417
+7,336
| +61% | +$461K | 0.92% | 35 |
|
|
2016
Q4 | $757K | Sell |
12,081
-664
| -5% | -$40.5K | 0.61% | 64 |
|
|
2016
Q3 | $804K | Sell |
12,745
-82
| -0.6% | -$5.31K | 0.71% | 51 |
|
|
2016
Q2 | $854K | Buy |
12,827
+32
| +0.3% | +$1.95K | 0.86% | 45 |
|
|
2016
Q1 | $731K | Buy |
+12,795
| New | +$713K | 0.81% | 47 |
|
Other funds holding ABBV
Mirador Capital Partners's ABBV Position: Q2 2026 in Review
Mirador Capital Partners increased its AbbVie (ABBV) stake by 4.4% in Q2 2026, buying an estimated $620K and bringing the position to 68,762 shares worth $17.3M. The position accounts for 2.12% of the portfolio, ranked #10.
Mirador Capital Partners first reported a position in ABBV in Q1 2016 and has held it in 42 quarters since. 4,190 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Mirador Capital Partners held 68,762 shares of AbbVie worth $17.3M as of Q2 2026.
- Mirador Capital Partners bought 2,881 AbbVie shares in Q2 2026, an estimated $620K.
- AbbVie made up 2.12% of Mirador Capital Partners's portfolio in Q2 2026, its #10 holding.
- Mirador Capital Partners first reported a position in AbbVie in Q1 2016 and has held it in 42 quarters since.
- 4,190 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Mirador Capital Partners's 13F filing for Q2 2026, filed 7 Jul 2026.